Company / Return on Equity (ROE)
Ovid Therapeutics Inc. Return on Equity (ROE) History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-38.7%
FY2025
5-year range
-59.6% / 68.3%
FY2022-FY2025
Trend
+35.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Ovid Therapeutics Inc. reports negative total equity of -38.7% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-38.7% in FY2025 with a 3-year CAGR of -107.1%.
Improved from -40.9% to -38.7% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -107.1pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 35.0% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.61 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -38.7% | +35.0% |
| FY2024 | -59.6% | -45.6% |
| FY2023 | -40.9% | -159.9% |
| FY2022 | 68.3% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026